Skip to main content
Frontiers in Psychiatry logoLink to Frontiers in Psychiatry
. 2021 May 21;12:677934. doi: 10.3389/fpsyt.2021.677934

Long Haulers—What Is the Evidence for Post-COVID Fatigue?

Andreas Stengel 1,2,*, Nisar Malek 3, Stephan Zipfel 1, Siri Goepel 3,4
PMCID: PMC8175784  PMID: 34093286

Introduction

Since the start of the pandemic until now (end of February 2021), more than 113 million people worldwide have been infected (encompassing people with and without symptoms) with SARS-CoV-2, with 89 million of those (78.8%) being classified as recovered (1). However, it became more and more apparent that people infected can have symptoms not only in the acute phase but also with a considerable delay. A recent meta-analysis from 15 studies encompassing 47,910 patients showed that 80% of patients develop at least one symptom during follow–up times ranging from 2 weeks to 4 months post viral infection (2). This condition is termed heterogeneously, namely, long COVID, post-COVID, or recently post-acute sequelae of SARS-CoV2 (PASC). The most common symptoms were fatigue (58%), headache (44%), attention disorder (27%), hair loss (25%), and dyspnea (24%) (Table 1) (2). The long-term outcome of these symptoms remains to be investigated. The current opinion article will discuss the current state of knowledge on the development of long COVID symptoms with a special focus on post-COVID fatigue being the most common symptom.

Table 1.

Common symptoms of long COVID.

Symptom Percentage
Fatigue 58
Headache 44
Attention disorder 27
Hair loss 25
Dyspnea 24
Ageusia 23
Anosmia 21
Polypnea 21
Cough 19
Joint pain 19
Sweating 17
Memory loss 16
Nausea 16
Chest pain/discomfort 16
Hearing loss/tinnitus 15
Anxiety 13
Depression 12
Digestive disorders 12
Cutaneous signs 12
Weight loss 12
Sleep disorder 11
Fever 11
Pain 11
Resting heart rate increase 11
Palpitations 11

Data are derived from Lopez-Leon et al. (2). Data are derived from 15 studies encompassing 47,910 patients.

Discussion

Early on, it was reported that patients after hospitalization due to SARS-CoV-2 infection may develop persistent breathlessness (53%) and cough (34%) during the following months post discharge (3). Among those patients, one third had persistently elevated d-dimer levels; in 10% of patients, the C-reactive protein levels were elevated (3), giving rise to an ongoing inflammatory reaction. This was also reflected in a high percentage (38%) of pathological chest x-rays likely due to active endothelitis/vasculitis as recently discussed (4). Several risk factors for the development of these persistent symptoms have been identified: besides the severity of the initial SARS-CoV-2 infection, higher age, higher body mass index, and pre-existing lung diseases were associated with a greater risk (5).

Interestingly, the majority of these patients described above also reported other symptoms. Two thirds (69%) also complained about fatigue; another 13 and 12% patients showed signs of anxiety and depression, respectively (3). However, another publication showed that fatigue developed irrespective of a preceding hospitalization and was therefore not associated with the severity of the initial SARS-CoV-2 disease (6). Moreover, female sex (7) and previous episodes of depression or anxiety were observed more often in patients developing fatigue (6), which contrasts with the risk factors for the development of the vascular long COVID symptoms. A perceived high level of perceived social stigmatization due to the infection status was associated with an increased risk of developing impaired general mental health post SARS-CoV-2 infection, while a high level of social support showed the opposite association (8).

Patients with fatigue did not show differences in autonomic functions (assessed using electrocardiogram and blood pressure monitoring during deep breathing, active standing, Valsalva maneuver, and cold-pressor testing) compared to subjects that underwent a SARS-CoV-2 infection without developing fatigue (9). This gives rise to a functional origin of the fatigue symptoms.

It is well-known that irritable bowel syndrome (IBS), a highly prevalent (worldwide prevalence around 10–15%) functional gastrointestinal disorder (10), can develop after acute gastroenteritis, also known as post-infectious IBS (11). Symptoms often encompass diarrhea and abdominal pain, being not different from those of a non-post-infectious genesis of IBS (10). Likewise, the treatment does not differ as no persistent inflammatory changes are present that would explain the magnitude of complaints (10). Therefore, also these complaints are classified as functional. The current pathogenetic model explaining the pathogenesis of functional disorders is the biopsychosocial model encompassing biological (e.g., genetic factors) and psycho-social (e.g., life events, acute triggering somatic, or psychological stressors) factors (12). According to the new International Classification of Diseases 11th revision (ICD-11), this will be best categorized as bodily distress disorder, “characterized by the presence of bodily symptoms that are distressing to the individual and excessive attention directed toward the symptoms which may be manifest by repeated contact with health care providers” (13). “Typically, the disorder involves multiple bodily symptoms that may vary over time. Occasionally there is a single symptom—usually pain or fatigue—that is associated with the other features of the disorder” (13).

In summary, a SARS-CoV-2-infection might trigger post-COVID fatigue as a variant of long COVID. Whether this is specific for SARS-CoV-2 or rather a broader risk factor for the development of a functional disease/bodily distress disorder as observed before for, e.g., post-infectious IBS, will have to be further investigated. Moreover, more emphasis should be given to the characterization of risk factors for the development of functional post-COVID symptoms so patients at higher risk can be given higher attention in a personalized approach, screened early, and provided early help to avoid over-diagnosing and iatrogenic somatic fixation. Hereby, the close collaboration of internal medicine practitioners and those specialized in psychosomatic medicine/psychiatry is key to offer treatment in an integrated manner. It is likely that treatments encouraging active participation of patients (e.g., exercise or psychotherapy) might be more effective than passive options (e.g., medication alone) as described for other functional disorders before (14).

Author Contributions

AS prepared the first draft of the article. All authors critically reviewed and finalized the opinion article.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Footnotes

Funding. We acknowledge support by Deutsche Forschungsgemeinschaft and the Open Access Publishing Fund of the University of Tübingen.

References

  • 1.WHO . WHO Coronavirus (COVID-19) Dashboard. Available online at: https://covid19.who.int/ (accessed February 28, 2021).
  • 2.Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. medRxiv. (2021). 10.1101/2021.01.27.21250617 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Mandal S, Barnett J, Brill SE, Brown JS, Denneny EK, Hare SS, et al. 'Long-COVID': a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax. (2020). 10.1136/thoraxjnl-2020-215818. [Epub ahead of print]. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Sollini M, Ciccarelli M, Cecconi M, Aghemo A, Morelli P, Gelardi F, et al. Vasculitis changes in COVID-19 survivors with persistent symptoms: an [(18)F]FDG-PET/CT study. Eur J Nucl Med Mol Imaging. (2021) 48:1460–6. 10.1007/s00259-020-05084-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Halpin SJ, McIvor C, Whyatt G, Adams A, Harvey O, McLean L, et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation. J Med Virol. (2021) 93:1013–22. 10.1002/jmv.26368 [DOI] [PubMed] [Google Scholar]
  • 6.Townsend L, Dowds J, O'Brien K, Sheill G, Dyer AH, O'Kelly B, et al. Persistent poor health post-COVID-19 is not associated with respiratory complications or initial disease severity. Ann Am Thorac Soc. (2021). 10.1513/AnnalsATS.202009-1175OC. [Epub ahead of print]. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. (2021) 397:220–32. 10.1016/S0140-6736(20)32656-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Qi R, Chen W, Liu S, Thompson PM, Zhang LJ, Xia F, et al. Psychological morbidities and fatigue in patients with confirmed COVID-19 during disease outbreak: prevalence and associated biopsychosocial risk factors. medRxiv. (2020). 10.1101/2020.05.08.20031666 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Townsend L, Moloney D, Finucane C, McCarthy K, Bergin C, Bannan C, et al. Fatigue following COVID-19 infection is not associated with autonomic dysfunction. PLoS ONE. (2021) 16:e0247280. 10.1371/journal.pone.0247280 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Enck P, Aziz Q, Barbara G, Farmer AD, Fukudo S, Mayer EA, et al. Irritable bowel syndrome. Nat Rev Dis Primers. (2016) 2:16014. 10.1038/nrdp.2016.14 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Schwille-Kiuntke J, Mazurak N, Enck P. Systematic review with meta-analysis: post-infectious irritable bowel syndrome after travellers' diarrhoea. Aliment Pharmacol Ther. (2015) 41:1029–37. 10.1111/apt.13199 [DOI] [PubMed] [Google Scholar]
  • 12.Henningsen P, Zipfel S, Sattel H, Creed F. Management of functional somatic syndromes and bodily distress. Psychother Psychosom. (2018) 87:12–31. 10.1159/000484413 [DOI] [PubMed] [Google Scholar]
  • 13.First MB, Reed GM, Hyman SE, Saxena S. The development of the ICD-11 clinical descriptions and diagnostic guidelines for mental and behavioural disorders. World Psychiatry. (2015) 14:82–90. 10.1002/wps.20189 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Henningsen P, Zipfel S, Herzog W. Management of functional somatic syndromes. Lancet. (2007) 369:946–55. 10.1016/S0140-6736(07)60159-7 [DOI] [PubMed] [Google Scholar]

Articles from Frontiers in Psychiatry are provided here courtesy of Frontiers Media SA

RESOURCES